Compared side by side
5-Amino-1MQ vs semaglutide: how they differ
The short answer
Semaglutide is a GLP-1 receptor agonist that reduces appetite and slows stomach emptying; 5-Amino-1MQ is a small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, and in obese mice it cut weight and fat without reducing food intake. Semaglutide is FDA-approved, with about 15% average weight loss at 68 weeks in its main trial, and 5-Amino-1MQ has no human studies. Commonly reported: “food noise” going quiet on semaglutide, and nothing to feel on 5-Amino-1MQ, though some describe easier fat loss alongside a deficit or a GLP-1.
Side by side
| Compared | 5-Amino-1MQ | Semaglutide |
|---|---|---|
| Category | Metabolic & GLP-1 | Metabolic & GLP-1 |
| Also known as | 5-A-1MQ, 5Amino1MQ, 5-Amino-1-methylquinolinium | Ozempic, Wegovy |
| What it is | A small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy. | A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. |
| How it works | NNMT (Nicotinamide N-methyltransferase) inhibitor that blocks NNMT activity in fat cells. In cultured fat cells it raises NAD+ and SAM levels; in obese mice it cut body weight and fat without reducing food intake, and with a reduced-calorie diet lean mass made up a larger share of body weight. No human data. | GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects. |
| Commonly reported | Nothing to feel, though some describe easier fat loss alongside a deficit or a GLP-1. There are no human studies, and the mouse work used injections rather than oral doses. | The constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial. |
| Studied range | Research range: 50–100 mg. Studied in research — not a recommendation. | FDA label: 0.25–2.4 mg, starting dose 0.25 mg. |
| How often | Daily | Weekly SubQ |
| Half-life | Unknown | ~1 week (FDA label) |
| Route | Oral | SubQ injection |
| Typical run | Very limited data. Some run 8–12 weeks then cycle off. Preclinical compound — approach conservatively. | FDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers. |
| Evidence | Emerging: primarily preclinical / limited human data | Established: clinical trials or FDA-approved use exists |
| Common side effects | Limited human data, generally well tolerated in early research | Nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk |
- Category
- 5-Amino-1MQMetabolic & GLP-1
- SemaglutideMetabolic & GLP-1
- Also known as
- 5-Amino-1MQ5-A-1MQ, 5Amino1MQ, 5-Amino-1-methylquinolinium
- SemaglutideOzempic, Wegovy
- What it is
- 5-Amino-1MQA small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy.
- SemaglutideA GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying.
- How it works
- 5-Amino-1MQNNMT (Nicotinamide N-methyltransferase) inhibitor that blocks NNMT activity in fat cells. In cultured fat cells it raises NAD+ and SAM levels; in obese mice it cut body weight and fat without reducing food intake, and with a reduced-calorie diet lean mass made up a larger share of body weight. No human data.
- SemaglutideGLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves glucose metabolism. FDA-approved for T2DM and obesity. Titrate dose slowly to minimize GI side effects.
- Commonly reported
- 5-Amino-1MQNothing to feel, though some describe easier fat loss alongside a deficit or a GLP-1. There are no human studies, and the mouse work used injections rather than oral doses.
- SemaglutideThe constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.
- Studied range
- 5-Amino-1MQResearch range: 50–100 mg. Studied in research — not a recommendation.
- SemaglutideFDA label: 0.25–2.4 mg, starting dose 0.25 mg.
- How often
- 5-Amino-1MQDaily
- SemaglutideWeekly SubQ
- Half-life
- 5-Amino-1MQUnknown
- Semaglutide~1 week (FDA label)
- Route
- 5-Amino-1MQOral
- SemaglutideSubQ injection
- Typical run
- 5-Amino-1MQVery limited data. Some run 8–12 weeks then cycle off. Preclinical compound — approach conservatively.
- SemaglutideFDA-approved for ongoing use. Community uses indefinitely or until goal weight reached, then tapers.
- Evidence
- 5-Amino-1MQEmerging: primarily preclinical / limited human data
- SemaglutideEstablished: clinical trials or FDA-approved use exists
- Common side effects
- 5-Amino-1MQLimited human data, generally well tolerated in early research
- SemaglutideNausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
5-Amino-1MQ
- Day 1–28 Quiet compound, slow signal
- Day 28–84 Recomp in a deficit
- Day 84–168 Cycle decision point
Semaglutide
- Day 1–28 · 0.25 mg Gut is adapting
- Day 29–56 · 0.5 mg Appetite shifts are real now
- Day 57–112 · 1 mg Clinically useful weight loss kicks in
- Day 113–140 · 1.7 mg Max submaximal step
- Day 141–364 · 2.4 mg Full dose — the working dose
- Day 365+ Plateau territory — new baseline
Together or one or the other
5-Amino-1MQ and semaglutide are a common stack: 5-Amino-1MQ lists semaglutide among its common stacks.
Community · 5-Amino-1MQ
Layered onto a GLP-1 cut
Common community pattern: 5-Amino-1MQ layered onto an ongoing GLP-1 protocol. The GLP-1 drives the calorie deficit while 5-Amino-1MQ helps protect lean mass from the fat-cell side (a mouse finding). Commonly reported: some find recomposition a bit easier; others notice no change.
Questions people ask
How long do 5-Amino-1MQ and semaglutide last?
The half-life of 5-Amino-1MQ is unknown. The half-life of semaglutide is ~1 week (FDA label).
How often are 5-Amino-1MQ and semaglutide taken?
5-Amino-1MQ: daily. Route: Oral. Semaglutide: weekly SubQ. Route: SubQ injection.
How are 5-Amino-1MQ and semaglutide dosed in research?
The research range for 5-Amino-1MQ is 50–100 mg. Studied in research — not a recommendation. The FDA label range for semaglutide is 0.25–2.4 mg, with a 0.25 mg starting dose.
What are the common side effects of 5-Amino-1MQ and semaglutide?
For 5-Amino-1MQ, the library lists: limited human data, generally well tolerated in early research. For semaglutide: nausea, vomiting, diarrhea, constipation, decreased appetite, fatigue, pancreatitis risk.
Are 5-Amino-1MQ and semaglutide taken together?
5-Amino-1MQ and semaglutide are a common stack: 5-Amino-1MQ lists semaglutide among its common stacks. Common community pattern: 5-Amino-1MQ layered onto an ongoing GLP-1 protocol. The GLP-1 drives the calorie deficit while 5-Amino-1MQ helps protect lean mass from the fat-cell side (a mouse finding). Commonly reported: some find recomposition a bit easier; others notice no change.